CN103476406B - 安它可朋组合物 - Google Patents
安它可朋组合物 Download PDFInfo
- Publication number
- CN103476406B CN103476406B CN201180070146.8A CN201180070146A CN103476406B CN 103476406 B CN103476406 B CN 103476406B CN 201180070146 A CN201180070146 A CN 201180070146A CN 103476406 B CN103476406 B CN 103476406B
- Authority
- CN
- China
- Prior art keywords
- entacapone
- composition
- sds
- pvp
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims abstract description 58
- 229960003337 entacapone Drugs 0.000 claims abstract description 57
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 229920003081 Povidone K 30 Polymers 0.000 claims description 19
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 206010020741 Hyperpyrexia Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229960004205 carbidopa Drugs 0.000 description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本发明公开了一种安他可朋组合物，其包含安它可朋或其医药可接受盐，PVPK30及SDS；其中安它可朋：PVP K30：SDS的质量比为1：0.05～0.6：0.06～0.1。本发明还公开了安他可朋组合物的制备方法和应用。
Description
技术领域
本发明是关于一种安它可朋(Entacapone)组合物，其包含安它可朋、PVP K30及SDS。此外，本发明亦关于所述安它可朋组合物的制备方法及其用途。
背景技术
安它可朋即(E)-2-氰基-3-(3，4-二羟基-5-硝基-苯基)-N，N-二乙基-2-丙烯酰胺((E)-2-cyano-3-(3，4-dihydroxy-5-nitro-phenyl)-N，N-diethyl-2-propenamide)，是目前已知可用于治疗帕金森氏症(Parkinson′s Disease)的药物。
由于安它可朋的溶离率及生体可用率低，目前已知的安它可朋组合物多以研磨或粉碎的方式将之制成尺寸较小的颗粒，以提高其溶离率及生体可用率。举例来说，US 2010/0104634 A1是使90％的安它可朋颗粒粒径小于40μm，而WO 2009098661 A1则是将安它可朋与糖醇的颗粒经微粒化工艺而使其粒径小于30μm。
然而，研磨或微粒化这类工艺往往会产生高热，而使药物变质，另外，此类工艺仍有产率低及成本高的问题。因此，如何在毋须研磨、粉碎或微粒化等工艺的情况下制备出溶离率或生体可用率高的安它可朋组合物，是业界亟待解决的课题。
发明内容
为解决上述问题，发明人开发出一种改良方法，能够在毋须研磨、粉碎或微粒化等工艺的情况下提高安它可朋的溶离率，并使工艺简化以提高产率及降低生产成本。
本发明目的之一是提供一种安它可朋组合物，其包含安它可朋或其医药可接受盐、PVP K30(Polyvinylpyrrolidone K30)、SDS(sodium dodecyl sulfate)，以及至少一种医药上可接受的赋形剂。
为达上述目的，本发明提供了一种安它可朋组合物，其包含安它可朋或其医药可接受盐、PVP K30及SDS；其中安它可朋∶PVP K30∶SDS的质量比为1∶0.05～0.6∶0.06～0.1，且其溶离率大于88％。
在本发明的较佳实施态样中，所述安它可朋组合物中的安它可朋∶PVPK30∶SDS的质量比为1∶0.05～0.2∶0.06；更佳者，其质量比为1∶0.2∶0.06。
在本发明的较佳实施态样中，所述安它可朋组合物的溶离率大于90％；更佳者，其溶离率大于95％。
在本发明的较佳实施态样中，所述安它可朋组合物进一步包含至少一种赋形剂，且所述赋形剂是选自聚维酮(Povidone)、交联聚维酮(Crospovidone)、糖类、交联羧甲基纤维素钠(Croscarmellose Sodium)，或其组合。所述糖类例如可选自微晶纤维素(Microcrystalline Cellulose，MCC)、甘露糖醇(Mannitol)、纤维素、羟丙基甲基纤维素(Hydroxypropyl Methylcellulose)、淀粉或乳糖。
本发明还提供了一种如前文所述的安它可朋组合物的制备方法，其包含下列步骤：
(a)将安它可朋或其医药可接受盐、PVP K30及SDS混合，其中安它可朋∶PVP K30∶SDS的质量比为1∶0.05～0.6∶0.06～0.1；
(b)使步骤(a)所得的混合物通过筛网，且该筛网的网目在180μm以下，更佳者，在150μm以下；
(c)将步骤(b)所得的混合物进行造粒；
(d)将步骤(c)所得的颗粒烘干，直至水分含量介于1％～3％，得出所述的安它可朋组合物；
以上方法不包含使安它可朋或其医药可接受盐、PVP K30及SDS的混合物的粒径小于30μm的研磨、粉碎或微粒化步骤。
在本发明的较佳实施态样中，所述方法步骤(a)中的安它可朋∶PVP K30∶SDS的质量比为1∶0.05～0.2∶0.06；更佳者，其质量比为1∶0.2∶0.06。
在本发明的较佳实施态样中，所述方法步骤(c)的造粒为湿式造粒。
在本发明的较佳实施态样中，所述方法不包含使安它可朋或其医药可接受盐、PVPK30及SDS的混合物的粒径小于40μm的研磨、粉碎或微粒化步骤。
在本发明的较佳实施态样中，所述方法步骤(a)进一步包含至少一种赋形剂，且所述赋形剂选自聚维酮、交联聚维酮、糖类、交联羧甲基纤维素钠，或其组合。所述糖类例如可选自微晶纤维素、甘露糖醇、纤维素、羟丙基甲基纤维素、淀粉或乳糖。
本发明另提供一种医药组合物，其包含如前文所述的安它可朋组合物；较佳者，是治疗帕金森氏症的医药组合物。
在本发明的较佳实施态样中，所述医药组合物进一步包含左多巴(Levodopa)及羟苯丝肼(Benserazide)、或进一步包含左多巴及卡比多巴(Carbidopa)。
本发明又提供一种将如前文所述的安它可朋组合物用于制备医药组合物的用途；较佳者，是用于制备治疗帕金森氏症的医药组合物。
在本发明的较佳实施态样中，所述用途所制备的医药组合物进一步包含左多巴及羟苯丝肼、或进一步包含左多巴及卡比多巴。
由上可知，本发明所提供的安它可朋组合物可在毋须研磨、粉碎或微粒化等工艺的情况下将安它可朋的溶离率提高到88％以上，与习知方法相较之下，不但省略研磨相关步骤而简化工艺，同时不会因为研磨相关步骤而导致高热而引发安它可朋变质的风险，亦可使产率提高，成本降低。
具体实施方式
下列实施例仅为最佳实施态样的例示，非意图限制本发明的范围。所属领域的技术人员可藉由本发明的揭露，在不背离本发明的精神的范围内做出适度的变更和修正。
实施例
首先依照下表1的组合物配比，制得安它可朋组合物1～6的颗粒。
将MCC、SDS、PVP K30、甘露糖醇及安它可朋依序混合5分钟，之后使混合物粉末通过150μm(100目)的筛网；再将通筛后的粉末倒入造粒机中，喷洒去离子水，以进行造粒。所得颗粒置于50℃烘箱中烘干，直至水分含量介于1％～3％，之后充入胶囊或是打锭，得出安它可朋组合物1～6。
表1
依据在FDA网站上提供的溶离方法数据库(Dissolution Methods Database)中检索得到安它可朋的药物溶离方法(http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm)进行溶离试验，其中溶离是使用USP标准搅拌桨式装置(paddle)，转速为50rpm，所用溶媒为900mL的pH5.5的磷酸缓冲溶液，试验时间为120分钟，之后利用HPLC进行分析，所得溶离率如下表2所示。
表2
由上可知，安它可朋本身的溶离率大约是81.15％，当安它可朋∶PVPK30∶SDS的质量比为1∶0.05～0.6∶0.06～0.1之时，所得安它可朋组合物的溶离率大幅增加，可达88％以上；当安它可朋∶PVP K30∶SDS的质量比为1∶0.05～0.2∶0.06之时，所得安它可朋组合物的溶离率可达90％以上；而当安它可朋∶PVP K30∶SDS的质量比为1∶0.2∶0.06时，其溶离率可达95％以上。
因此，利用上述配比在毋须研磨、粉碎或微粒化等工艺的情况下所得出的安它可朋组合物不但具有溶离率高、工艺简便等优点，亦没有因为研磨时产生高热而导致安它可朋变质的疑虑。
Claims (7)
1.一种安它可朋组合物的制备方法，其包含下列步骤：
(a)将MCC、SDS、PVP K30、甘露糖醇及安它可朋依序混合5分钟，其中每200mg的安它可朋，PVP K30、SDS、MCC及甘露糖醇的含量分别为10mg、12mg、0.5mg及168mg；或每200mg的安它可朋，PVP K30、SDS、MCC及甘露糖醇的含量分别为20mg、12mg、0.5mg及168mg；
(b)使步骤(a)所得的混合物通过150μm的筛网；
(c)将步骤(b)所得的混合物喷洒去离子水进行造粒；
(d)将步骤(c)所得的颗粒于50℃烘干，直至水分含量介于1％～3％，得出颗粒形式的安它可朋组合物；
以上方法不包含使安它可朋、PVP K30及SDS的混合物的粒径小于30μm的研磨、粉碎或微粒化步骤。
2.如权利要求1所述的方法，其中步骤(c)的造粒为湿式造粒。
3.如权利要求1所述的方法，其不包含使安它可朋、PVP K30及SDS的混合物的粒径小于40μm的研磨、粉碎或微粒化步骤。
4.一种安它可朋组合物，其包含安它可朋、PVP K30、SDS、MCC及甘露糖醇；其中每200mg的安它可朋，PVP K30、SDS、MCC及甘露糖醇的含量分别为10mg、12mg、0.5mg及168mg；或每200mg的安它可朋，PVP K30、SDS、MCC及甘露糖醇的含量分别为20mg、12mg、0.5mg及168mg；并且，所述安它可朋组合物为颗粒形式，且该组合物是以权利要求1-3中任一项所述的方法所制得的。
5.一种医药组合物，其包含如权利要求4所述的安它可朋组合物。
6.如权利要求5所述的医药组合物，其是治疗帕金森氏症的医药组合物。
7.一种将如权利要求4所述的安它可朋组合物用于制备用于治疗帕金森氏症的医药组合物的用途。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/073297 WO2012145893A1 (zh) | 2011-04-26 | 2011-04-26 | 安它可朋组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103476406A CN103476406A (zh) | 2013-12-25 |
| CN103476406B true CN103476406B (zh) | 2017-05-24 |
Family
ID=47071548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180070146.8A Expired - Fee Related CN103476406B (zh) | 2011-04-26 | 2011-04-26 | 安它可朋组合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140120166A1 (zh) |
| EP (1) | EP2702991A4 (zh) |
| JP (1) | JP5855230B2 (zh) |
| KR (1) | KR101807907B1 (zh) |
| CN (1) | CN103476406B (zh) |
| AU (1) | AU2011366717B2 (zh) |
| BR (1) | BR112013027219A2 (zh) |
| CA (1) | CA2833443C (zh) |
| EA (1) | EA025627B1 (zh) |
| MX (1) | MX2013012429A (zh) |
| WO (1) | WO2012145893A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101974752B1 (ko) * | 2017-12-31 | 2019-09-05 | 황혜미 | 욕창 치료용 크림 및 이를 제조하는 방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081268A2 (en) * | 2006-12-27 | 2008-07-10 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone |
| WO2009098661A1 (en) * | 2008-02-06 | 2009-08-13 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| AU2002222567B2 (en) * | 2000-12-01 | 2007-05-10 | Kyowa Hakko Kirin Co., Ltd. | Composition improved in solubility or oral absorbability |
| EP1448169A1 (en) * | 2001-11-07 | 2004-08-25 | Fujisawa Pharmaceutical Co., Ltd. | Method for improving dissolution of poorly dispersible medicaments |
| CN1275593C (zh) * | 2004-02-13 | 2006-09-20 | 马晶 | 一种枸橼酸他莫昔芬分散片及其制法 |
| EA013161B1 (ru) * | 2005-06-08 | 2010-02-26 | Орион Корпорейшн | Дозированная форма для перорального применения |
| WO2007069274A2 (en) * | 2005-11-09 | 2007-06-21 | Torrent Pharmaceuticals Limited | Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent |
| NZ591326A (en) * | 2008-08-22 | 2012-12-21 | Wockhardt Research Center | An extended release pharmaceutical composition of entacapone or salts thereof |
| JP5718937B2 (ja) * | 2009-12-25 | 2015-05-13 | イノファーマックス インコーポレイテッド | パーキンソン病を治療するための医薬組成物及びその調製方法 |
-
2011
- 2011-04-26 EP EP11864150.5A patent/EP2702991A4/en not_active Withdrawn
- 2011-04-26 CN CN201180070146.8A patent/CN103476406B/zh not_active Expired - Fee Related
- 2011-04-26 KR KR1020137028892A patent/KR101807907B1/ko active IP Right Grant
- 2011-04-26 WO PCT/CN2011/073297 patent/WO2012145893A1/zh active Application Filing
- 2011-04-26 JP JP2014506709A patent/JP5855230B2/ja not_active Expired - Fee Related
- 2011-04-26 US US14/114,032 patent/US20140120166A1/en not_active Abandoned
- 2011-04-26 BR BR112013027219A patent/BR112013027219A2/pt not_active Application Discontinuation
- 2011-04-26 CA CA2833443A patent/CA2833443C/en not_active Expired - Fee Related
- 2011-04-26 EA EA201301197A patent/EA025627B1/ru not_active IP Right Cessation
- 2011-04-26 MX MX2013012429A patent/MX2013012429A/es unknown
- 2011-04-26 AU AU2011366717A patent/AU2011366717B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081268A2 (en) * | 2006-12-27 | 2008-07-10 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone |
| WO2009098661A1 (en) * | 2008-02-06 | 2009-08-13 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014512395A (ja) | 2014-05-22 |
| EA201301197A1 (ru) | 2014-02-28 |
| EP2702991A1 (en) | 2014-03-05 |
| MX2013012429A (es) | 2013-12-06 |
| EP2702991A4 (en) | 2015-02-18 |
| US20140120166A1 (en) | 2014-05-01 |
| KR20140024879A (ko) | 2014-03-03 |
| JP5855230B2 (ja) | 2016-02-09 |
| CN103476406A (zh) | 2013-12-25 |
| KR101807907B1 (ko) | 2017-12-11 |
| BR112013027219A2 (pt) | 2016-12-27 |
| AU2011366717A1 (en) | 2013-11-07 |
| CA2833443A1 (en) | 2012-11-01 |
| EA025627B1 (ru) | 2017-01-30 |
| AU2011366717B2 (en) | 2017-06-15 |
| CA2833443C (en) | 2017-11-07 |
| WO2012145893A1 (zh) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537530A5 (zh) | ||
| CN104306344B (zh) | 一种阿齐沙坦片剂及其制备工艺 | |
| CN102793685A (zh) | 含有普瑞巴林的口服胶囊及其制备方法 | |
| EP2508172A1 (en) | Stable and uniform formulations of entecavir and preparation method thereof | |
| CN105358137A (zh) | Sovaprevir片剂 | |
| CN103476406B (zh) | 安它可朋组合物 | |
| CN102895203A (zh) | 一种阿奇霉素分散片的制备方法 | |
| CN103356498A (zh) | 枸橼酸莫沙必利缓释片 | |
| CN103933001A (zh) | 一种稳定的赛洛多辛口服固体药物组合物及其制备方法 | |
| CN109464442A (zh) | 一种沙库巴曲缬沙坦钠药物组合物及其制备方法 | |
| CN103284952A (zh) | 一种含有非诺贝特的药物组合物 | |
| CN109953969A (zh) | 一种缬沙坦氨氯地平片的制备方法 | |
| CN107375231A (zh) | 一种奥拉帕尼组合物胶囊的制备方法 | |
| JP2008169135A (ja) | グリメピリド組成物の製造方法 | |
| CN104055741A (zh) | 一种孟鲁司特钠片剂及其制备方法 | |
| CN103405394A (zh) | 一种酒石酸美托洛尔缓释片及其制备方法 | |
| TWI419685B (zh) | 安它可朋組成物 | |
| CN107913254A (zh) | 一种替格瑞洛分散片及其制备方法 | |
| CN106236727B (zh) | 一种安乃近泡腾片及其制备方法 | |
| CN105030703B (zh) | 一种防治疗栓塞性疾病的利伐沙班片及其制备方法 | |
| CN105535980B (zh) | 稳定的瑞格列奈药物组合物及其制备方法 | |
| CN109419780A (zh) | 一种盐酸索他洛尔片剂及其制备方法 | |
| CN107375233A (zh) | 一种奥拉帕尼组合物胶囊的制备方法 | |
| Mupparaju et al. | Formulation and evaluation of dolutegravir sodium solid dispersions and fast dissolving tablets using poloxamer-188 and jackfruit seed starch as excipients | |
| CN104027316B (zh) | 一种格列美脲片剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1187269 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1187269 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170524 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |